Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis

Journal of Theoretical Biology

Volumn 220, Issue 4, 2003, Pages 545-554

  Hahnfeldt, Philip ^a,b   Folkman, Judah ^b,c   Hlatky, Lynn ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDICINE; TUMOR;

ANGIOGENESIS; ARTICLE; BODY BURDEN; CANCER CHEMOTHERAPY; CELL HETEROGENEITY; CELL POPULATION; DOSIMETRY; DRUG DOSE REGIMEN; DRUG SENSITIZATION; DRUG TARGETING; ENDOTHELIUM CELL; ERADICATION THERAPY; HUMAN; LOGIC; MAXIMUM TOLERATED DOSE; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE; TUMOR; TUMOR CELL; TUMOR RESISTANCE;

EID: 0037458325     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1006/jtbi.2003.3162     Document Type: Article

References (43)

1. ANDERSON G. R., STOLER D. L., BRENNER B. M. Cancer: the evolved consequence of a destabilized genome. BioEssays. 23:2001;1037-1046.
2. BALDI A., DRAGONETTI E., BATTISTA T., GROEGER A. M., ESPOSITO V., BALDI G., SANTINI D. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients. Anticancer Res. 20:2000;3923-3928.
3. BLACK W. C., WELCH H. G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. New Engl. J. Med. 328:1993;1237-1243.
4. BOEHM T., FOLKMAN J., BROWDER T., O'REILLY M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
5. BRAUNSCHWEIGER P. G., SCHIFFER L. M. Cell kinetic-directed sequential chemotherapy with cyclophosphamide and adriamycin in T1699 mammary tumors. Cancer Res. 40:1980;737-743.
6. BRENNER D. J., HLATKY L. R., HAHNFELDT P. J., HUANG Y., SACHS R. K. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat. Res. 150:1998;83-91.
7. BROWDER T., BUTTERFIELD C. E., KRALING B. M., SHI B., MARSHALL B., O'REILLY M. S., FOLKMAN J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.
8. DILLEHAY L. E. A model of cell killing by low-dose-rate radiation including repair of sublethal damage, G2 block, and cell division. Radiat. Res. 124:1990;201-207.
9. DRIXLER T., BOREL RINKES I. H. M., RITCHIE E. D., VAN VROONHOVEN T. J. M. V., GEBBINK M. F. B. G., VOEST E. E. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 60:2000;1761-1765.
10. ELLIS L. M., LIU W., AHMAD S. A., FAN F., JUNG Y. D., SHAHEEN R. M., REINMUTH N. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin. Oncol. 28:2001;94-104.
11. FIDLER J., ELLIS M. Chemotherapeutic drugs: more really is not better. Nat. Med. 6:2000;500-502.
12. FOLKMAN J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285:1971;1182-1186.
13. FOLKMAN J., HAHNFELDT P., HLATKY L. Cancer: looking outside the genome. Nat. Rev. Mol. Cell Biol. 1:2000;76-79.
14. FUSE E., KOBAYASHI T., INABA M., SUGIYAMA Y. Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics. Cancer Treat. Rev. 21:1995;133-157.
15. GABRA H., CAMERON D. A., LEE L. E., MACKAY J., LEONARD R. C. F. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. Br. J. Cancer. 74:1996;2008-2012.
16. GATELY S., KERBEL R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7:2001;427-436.
17. HAHNFELDT P., HLATKY L. Resensitization due to redistribution of cells in the phases of the cell cycle during arbitrary radiation protocols. Radiat. Res. 145:1996;134-143.
18. HAHNFELDT P., HLATKY L. Cell resensitization during protracted dosing of heterogeneous cell populations. Radiat. Res. 150:1998;681-687.
19. HAHNFELDT P., SACHS R. K. Radiation damage to a dynamic cell population. Arino O., Axelrod D., Kimmel M. Advances in Mathematical Population Dynamics: Molecules, Cells and Man. 6:1997;World Scientific, River Edge.
20. HAHNFELDT P., PANIGRAHY D., FOLKMAN J., HLATKY L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59:1999;4770-4775.
21. HAINSWORTH J. D., GRECO F. A. Etoposide: twenty years later. Ann. Oncol. 6:1995;325-341.
22. HALL E. J. Radiobiology for the Radiologist. 1988;J.B. Lippincott, Phila-delphia. p. 149-152.
23. HANAHAN D., BERGERS G., BERGSLAND E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105:2000;1045-1047.
24. HANSEN R. M., RYAN L., ANDERSON T., KRZYWDA B., QUEBBEMAN E., BENSON III A., HALLER D. G., TORMEY D. C. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl Cancer Inst. 88:1996;668-674.
25. HOLMGREN L., O'REILLY M. S., FOLKMAN J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:1995;149-153.
26. KAMEN B. A., RUBIN E., AISNER J., GLATSTEIN E. High-time chemotherapy or high time for low dose. J. Clin. Oncol. 18:2000;2935-2937.
27. KASIMIR-BAUER S., MAYER S., BOJKO P., BORQUEZ D., NEUMANN R., SEEBER S. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin. Cancer Res. 7:2001;1582-1589.
28. KERBEL R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays. 13:1991;31-36.
29. KLEMENT G., BARUCHEL S., RAK J., MAN S., CLARK K., HICKLIN D. J., BOHLEN P., KERBEL R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;R15-24.
30. KOHDA K., SAKAMAKI S., MATSUNAGA T., KUGA T., FUJIMI A., KONUMA Y., KUSAKABE T., KOGAWA K., AKIYAMA T., KOIKE K., HIRAYAMA Y., SASAGAWA Y., NOJIRI S., HIRATA Y., NISHISATO T., & NIITSU G. Y. Long-term survival and late-onset complications of cancer patients treated with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Hokkaido Society of Peripheral Blood Stem Cell Transplantation. Int. J. Hematol. 73:2001;251-257.
31. KRUGER W. H., KROGER N., TOGEL F., RENGES H., BADBARAN A., HORNUNG R., JUNG R., GUTENSOHN K., GIESEKING F., JANICKE F., ZANDER A. R. Disseminated breast cancer cells prior to and after high-dose therapy. J. Hematother. Stem Cell Res. 10:2001;681-689.
32. MROSS K. Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials. Drug Resist. Update. 3:2000;223-235.
33. NORTON L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 24:1997;S10-3-S10-10.
34. SACHS R. K., HAHNFELDT P., BRENNER D. J. The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. Int. J. Radiat. Biol. 72:1997;351-374.
35. SEIDMAN A. D., HUDIS C. A., ALBANEL J., TONG W., TEPLER I., CURRIE V., MOYNAHAN M. E., THEODOULOU M., GOLLUB M., BASELGA J., NORTON L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16:1998;3353-3361.
36. SKIPPER H. E. The effects of chemotherapy on the kinetics of leukemic cell behavior. Cancer Res. 25:1965;1544-1550.
37. SKIPPER H. E., SCHNABEL F. M. JR. Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat. Rep. 68:1984;43-61.
38. SKIPPER H. E., SCHNABEL F. M. JR., WILCOX W. S. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother. Rep. 35:1964;1-111.
39. SOFFER S. Z., KIM E., MOORE J. T., HUANG J., YOKOI A., MANLEY C., O'TOOLE K., MIDDLESWORTH W., STOLAR C., YAMASHIRO D., KANDEL J. Novel use of an established agent: topotecan is anti-angiogenic in experimental Wilms tumor. J. Pediat. Surg. 36:2001;1781-1784.
40. STADTMAUER E. A., O'NEILL A., GOLDSTEIN L. J., CRILLEY P. A., MANGAN K. F., INGLE J. N., BRODSKY I., MARTINO S., LAZARUS H. M., ERBAN J. K., SICKLES C., GLICK J. H. Conventional-dose chemo-therapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. New Engl. J. Med. 342:2000;1069-1076.
41. VENDITTI J. M., HUMPHREYS S. R., GOLDIN A. Investigation of the activity of cytoxan against leukemia L1210 in mice. Cancer Res. 19:1959;986-995.
42. WOLMARK N., PIEDBOIS P., BUYSE M., CARLSON R., RUSTUM Y., ERLICHMAN C. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16:1998;301-308.
43. ZAIDER M., MINERBO G. N. A mathematical model for cell cycle progression under continuous low-dose-rate irradiation. Radiat. Res. 133:1993;20-26.